{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:00:10Z","timestamp":1785301210728,"version":"3.55.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tice.2025.103217","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:11:48Z","timestamp":1762272708000},"page":"103217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CRISPR\/Cas9 gene editing in muscle-related genetic disorders: Restoring function and exercise capacity"],"prefix":"10.1016","volume":"98","author":[{"given":"Yanduo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2025.103217_bib1","series-title":"in Volpe's Neurology of the Newborn","first-page":"1074","article-title":"Muscle involvement and restricted disorders","author":"Darras","year":"2025"},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib2","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050720","article-title":"Dominantly inherited muscle disorders: understanding their complexity and exploring therapeutic approaches","volume":"17","author":"Findlay","year":"2024","journal-title":"Dis. Models Mech."},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib3","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.3390\/cimb46050255","article-title":"Recent therapeutic gene editing applications to genetic disorders","volume":"46","author":"Deneault","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00277-023-05457-2","article-title":"CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia","volume":"103","author":"Alayoubi","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.tice.2025.103217_bib5","first-page":"2025","article-title":"Validation of Duchenne muscular dystrophy candidate modifiers using a CRISPR-Cas9-based approach in zebrafish","author":"Lerma","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s44330-024-00019-y","article-title":"CRISPR-mediated generation and comprehensive phenotyping of Duchenne Muscular Dystrophy mouse models","volume":"1","author":"Arudkumar","year":"2024","journal-title":"BMC Methods"},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib7","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","article-title":"Recent Advances in CRISPR\/Cas9 delivery approaches for therapeutic gene editing of stem cells","volume":"19","author":"Lotfi","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.tice.2025.103217_bib8","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib9","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.7150\/thno.43360","article-title":"Advances in CRISPR\/Cas-based gene therapy in human genetic diseases","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"issue":"22","key":"10.1016\/j.tice.2025.103217_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib11","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib12","doi-asserted-by":"crossref","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tice.2025.103217_bib13","article-title":"Parallel Resonant Magnetic Field Generator for Biomedical Applications","author":"Lei","year":"2024","journal-title":"IEEE Trans. Biomed. Circuits Syst."},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.tice.2025.103217_bib15","first-page":"17","article-title":"Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies","author":"Haque","year":"2025","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.tice.2025.103217_bib16","article-title":"What doesn\u2019t kill us makes us stronger: insights from neuroscience studies and molecular genetics","volume":"59","author":"Gan","year":"2024","journal-title":"Curr. Opin. Behav. Sci."},{"key":"10.1016\/j.tice.2025.103217_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtn.2022.03.004","article-title":"Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice","volume":"28","author":"Karri","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.stemcr.2021.08.011","article-title":"CRISPR\/Cas9\/AAV9-mediated in vivo editing identifies MYC regulation of 3D genome in skeletal muscle stem cell","volume":"16","author":"He","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s44149-023-00065-z","article-title":"CRISPR-Cas9 mediated phage therapy as an alternative to antibiotics","volume":"3","author":"Balcha","year":"2023","journal-title":"Anim. Dis."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.gendis.2023.03.017","article-title":"CRISPR\/Cas9 system and its applications in nervous system diseases","volume":"11","author":"Jiang","year":"2024","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib21","doi-asserted-by":"crossref","first-page":"20469","DOI":"10.1038\/s41598-024-71540-x","article-title":"A user-friendly CRISPR\/Cas9 system for mutagenesis of Neurospora crassa","volume":"14","author":"Gr\u00fcttner","year":"2024","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.tice.2025.103217_bib22","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1007\/s00216-024-05301-0","article-title":"A Dual-mode platform for the rapid detection of Escherichia coli O157: H7 based on CRISPR\/Cas12a and RPA","volume":"416","author":"Luo","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.tice.2025.103217_bib23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55780","article-title":"Enhancement of homology-directed repair with chromatin donor templates in cells","volume":"9","author":"Cruz-Becerra","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.tice.2025.103217_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-020-00496-y","article-title":"Enhancing the antibacterial activities of sow milk via site-specific knock-in of a lactoferrin gene in pigs using CRISPR\/Cas9 technology","volume":"10","author":"Han","year":"2020","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","article-title":"Clinical applications of the CRISPR\/Cas9 genome-editing system: Delivery options and challenges in precision medicine","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis."},{"issue":"19","key":"10.1016\/j.tice.2025.103217_bib26","doi-asserted-by":"crossref","first-page":"2207512","DOI":"10.1002\/advs.202207512","article-title":"CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective","volume":"10","author":"Sahel","year":"2023","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary classification of CRISPR\u2013Cas systems: a burst of class 2 and derived variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib28","doi-asserted-by":"crossref","first-page":"1800085","DOI":"10.1002\/adtp.201800085","article-title":"Synthetic vehicles for encapsulation and delivery of CRISPR\/Cas9 gene editing machinery","volume":"2","author":"Carboni","year":"2019","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib29","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1038\/s41598-024-61167-3","article-title":"Generating an organ-deficient animal model using a multi-targeted CRISPR-Cas9 system","volume":"14","author":"Lim","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clon.2019.09.057","article-title":"Modelling the cancer phenotype in the era of CRISPR-Cas9 gene editing","volume":"32","author":"Stewart","year":"2020","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103217_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: Comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.tice.2025.103217_bib32","doi-asserted-by":"crossref","first-page":"1282295","DOI":"10.3389\/fphys.2023.1282295","article-title":"Muscle synergies in joystick manipulation","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.tice.2025.103217_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120908","article-title":"Genetically modified cell sheets in regenerative medicine and tissue engineering","volume":"275","author":"Jiang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.tice.2025.103217_bib34","series-title":"in Drug Delivery Systems for Musculoskeletal Tissues","first-page":"189","article-title":"Drug Delivery Systems for Muscles","author":"Naito","year":"2024"},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11431-023-2541-x","article-title":"Flexible assistance strategy of lower limb rehabilitation exoskeleton based on admittance model","volume":"67","author":"Kou","year":"2024","journal-title":"Sci. China Technol. Sci."},{"key":"10.1016\/j.tice.2025.103217_bib36","doi-asserted-by":"crossref","first-page":"1327397","DOI":"10.3389\/fnagi.2024.1327397","article-title":"Towards Human-like walking with Biomechanical and neuromuscular control features: personalized attachment point optimization method of Cable-Driven exoskeleton","volume":"16","author":"Chen","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.tice.2025.103217_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.omtm.2019.09.001","article-title":"A muscle hybrid promoter as a novel tool for gene therapy","volume":"15","author":"Piekarowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib38","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1109\/TCBB.2022.3143770","article-title":"Inferring latent microRNA-disease associations on a gene-mediated tripartite heterogeneous multiplexing network","volume":"19","author":"Li","year":"2022","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinforma."},{"issue":"s2","key":"10.1016\/j.tice.2025.103217_bib39","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2025.104379","article-title":"Prevalence and management of gastrointestinal complications in Duchenne muscular dystrophy: a retrospective cohort study","volume":"47","author":"Aihara","year":"2025","journal-title":"Brain Dev."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib41","first-page":"9627","article-title":"Proteomic profiling of the interface between the stomach wall and the pancreas in dystrophinopathy","volume":"31","author":"Dowling","year":"2021","journal-title":"Eur. J. Transl. Myol."},{"key":"10.1016\/j.tice.2025.103217_bib42","series-title":"Gastrointestinal dysfunction in ventilated patients with Duchenne muscular dystrophy","author":"Cascio","year":"2012"},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14804","article-title":"Motor dysfunction of the gut in Duchenne muscular dystrophy: a review","volume":"36","author":"Subhan","year":"2024","journal-title":"Neurogastroenterol. Motil."},{"issue":"23","key":"10.1016\/j.tice.2025.103217_bib44","doi-asserted-by":"crossref","first-page":"14779","DOI":"10.3390\/ijms232314779","article-title":"Clinical and molecular insights into gastrointestinal dysfunction in myotonic dystrophy types 1 & 2","volume":"23","author":"Peterson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib45","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1007\/s12035-023-03868-w","article-title":"Discovering promising biomarkers and therapeutic targets for duchenne muscular dystrophy: a multiomics meta-analysis approach","volume":"61","author":"Elasbali","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tice.2025.103217_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123694","article-title":"Methyltransferase-like 16 drives diabetic nephropathy progression via epigenetic suppression of V-set pre-B cell surrogate light chain 3","author":"Peng","year":"2025","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib47","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/genes15111489","article-title":"An updated analysis of exon-skipping applicability for duchenne muscular dystrophy using the UMD-DMD database","volume":"15","author":"Leckie","year":"2024","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ppul.25055","article-title":"Overview of gene therapy in spinal muscular atrophy and duchenne muscular dystrophy","volume":"56","author":"Abreu","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.tice.2025.103217_bib49","first-page":"1","article-title":"Gut microbes-muscle axis in muscle function and meat quality","author":"He","year":"2025","journal-title":"Sci. China Life Sci."},{"issue":"15","key":"10.1016\/j.tice.2025.103217_bib50","doi-asserted-by":"crossref","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","article-title":"DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials","volume":"100","author":"Muntoni","year":"2023","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.tice.2025.103217_bib51","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400969RR","article-title":"Lactobacillus delbrueckii alleviates lipopolysaccharide-induced muscle inflammation and atrophy in weaned piglets associated with inhibition of endoplasmic reticulum stress and protein degradation","volume":"38","author":"Zhong","year":"2024","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1667\/RADE-21-00183.1","article-title":"Satellite cells are activated in a rat model of radiation-induced muscle fibrosis","volume":"197","author":"Zeng","year":"2022","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/dmcn.14365","article-title":"Congenital myopathies: an update","volume":"62","author":"Claeys","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.tice.2025.103217_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102330","article-title":"Gene therapies for RyR1-related myopathies","volume":"68","author":"Marty","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"12","key":"10.1016\/j.tice.2025.103217_bib55","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib56","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2017.126","article-title":"Genome engineering: a new approach to gene therapy for neuromuscular disorders","volume":"13","author":"Nelson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tice.2025.103217_bib57","article-title":"Universit\u00e9 Paris-Saclay","author":"Bizot","year":"2023","journal-title":"Optim. exon Skipp. Ther. Treat. Duchenne Muscular Dystrophy"},{"key":"10.1016\/j.tice.2025.103217_bib58","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00401-020-02150-w","article-title":"Intracellular calcium leak as a therapeutic target for RYR1-related myopathies","volume":"139","author":"Kushnir","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00018-024-05229-9","article-title":"Molecular mechanisms and therapeutic strategies for neuromuscular diseases","volume":"81","author":"Zambon","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41587-019-0103-5","article-title":"Duchenne muscular dystrophy awaits gene therapy","volume":"37","author":"Jones","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11248-021-00278-3","article-title":"Animal models for researching approaches to therapy of Duchenne muscular dystrophy","volume":"30","author":"Zaynitdinova","year":"2021","journal-title":"Transgenic Res."},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib62","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajmg.a.38418","article-title":"Treating pediatric neuromuscular disorders: the future is now","volume":"176","author":"Dowling","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis","volume":"59","author":"Yang","year":"2023","journal-title":"J. Paediatr. Child Health"},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib64","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase i ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine repeats in neurodegenerative diseases","volume":"14","author":"Lieberman","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"R1","key":"10.1016\/j.tice.2025.103217_bib66","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1093\/hmg\/ddz131","article-title":"Genetic approaches to the treatment of inherited neuromuscular diseases","volume":"28","author":"Ravi","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tice.2025.103217_bib67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2021.11.024","article-title":"Time-controlled and muscle-specific CRISPR\/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene","volume":"27","author":"Cardinali","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib68","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.stemcr.2020.03.026","article-title":"Myogenic progenitor cell lineage specification by CRISPR\/Cas9-based transcriptional activators","volume":"14","author":"Kwon","year":"2020","journal-title":"Stem Cell Rep."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: mechanisms and therapies","volume":"14","author":"Von Haehling","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","article-title":"The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases","volume":"21","author":"Oveili","year":"2023","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib71","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1038\/ncomms15201","article-title":"miR-29b contributes to multiple types of muscle atrophy","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tice.2025.103217_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110771","article-title":"Therapeutic targeting of triple-negative breast cancer: a multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors","volume":"196","author":"Kamali","year":"2025","journal-title":"Comput. Biol. Med."},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib73","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ymthe.2020.03.005","article-title":"CRISPR\/Cas9-mediated miR-29b editing as a treatment of different types of muscle atrophy in mice","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib74","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/genes13050921","article-title":"Identification of the CKM gene as a potential muscle-specific safe harbor locus in pig genome","volume":"13","author":"Xiong","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.tice.2025.103217_bib75","first-page":"295","article-title":"Generation of double-muscled sheep and goats by CRISPR\/Cas9-mediated knockout of the myostatin gene","author":"Kalds","year":"2022"},{"key":"10.1016\/j.tice.2025.103217_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.842074","article-title":"Generation of heritable prominent double muscle buttock rabbits via novel site editing of myostatin gene using CRISPR\/Cas9 system","volume":"9","author":"Zheng","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.tice.2025.103217_bib77","article-title":"A MSTNDel273C mutation with FGF5 knockout sheep by CRISPR\/Cas9 promotes skeletal muscle myofiber hyperplasia via MEK-ERK-FOSL1 axis","volume":"12","author":"Chen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.tice.2025.103217_bib78","article-title":"In vivo study of key transcription factors in muscle satellite cells by CRISPR\/Cas9\/AAV9-sgRNA mediated genome editing","author":"He","year":"2019","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib79","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib80","doi-asserted-by":"crossref","first-page":"21238","DOI":"10.1038\/s41598-024-70075-5","article-title":"Correction of exon 2, exon 2\u20139 and exons 8\u20139 duplications in DMD patient myogenic cells by a single CRISPR\/Cas9 system","volume":"14","author":"Lemoine","year":"2024","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.tice.2025.103217_bib81","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41434-022-00336-3","article-title":"CRISPR\/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy","volume":"29","author":"Wang","year":"2022","journal-title":"Gene Ther."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib82","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo","volume":"26","author":"Duch\u00eane","year":"2018","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib83","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","article-title":"Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy","volume":"29","author":"Pickar-Oliver","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tice.2025.103217_bib84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","article-title":"CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients","volume":"9","author":"Provenzano","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib85","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11010-023-04759-3","article-title":"Production of duchenne muscular dystrophy cellular model using crispr-cas9 exon deletion strategy","volume":"479","author":"Alizadeh","year":"2024","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib86","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206324120","article-title":"Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle","volume":"120","author":"Morin","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib87","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40259-023-00632-3","article-title":"Dystrophin-and utrophin-based therapeutic approaches for treatment of duchenne muscular dystrophy: a comparative review","volume":"38","author":"Szwec","year":"2024","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib88","first-page":"9246825","article-title":"CRISPR\/Cas9 genome editing in LGMD2A\/R1 patient-derived induced pluripotent stem and skeletal muscle progenitor cells","volume":"2023","author":"Mavrommatis","year":"2023","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.tice.2025.103217_bib89","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.omtn.2023.01.004","article-title":"CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2","volume":"31","author":"Poyatos-Garc\u00eda","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tice.2025.103217_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-018-0648-4","article-title":"Long term follow-up and further molecular and histopathological studies in the LGMD1F sporadic TNPO3-mutated patient","volume":"6","author":"Gibertini","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib91","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100539RR","article-title":"Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model","volume":"35","author":"Bl\u00e1zquez-Bernal","year":"2021","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib92","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000337","article-title":"Novel mutation in TNPO3 causes congenital limb-girdle myopathy with slow progression","volume":"5","author":"Vihola","year":"2019","journal-title":"Neurology Genetics"},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib93","doi-asserted-by":"crossref","first-page":"239a","DOI":"10.1016\/j.bpj.2022.11.1401","article-title":"Gene therapy strategies using CRISPR\/Cas9 for RyR1-related myopathies","volume":"122","author":"Beaufils","year":"2023","journal-title":"Biophys. J."},{"key":"10.1016\/j.tice.2025.103217_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtn.2019.02.019","article-title":"Allele-specific CRISPR\/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes","volume":"16","author":"Rabai","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tice.2025.103217_bib95","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.nmd.2020.08.351","article-title":"HIGHLIGHTS ACROSS MYOLOGY: O. 14 Gene editing using CRISPR\/CAS9 in an animal model of nemaline myopathy","volume":"30","author":"Sabha","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.tice.2025.103217_bib96","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.nmd.2016.06.444","article-title":"Gene Therapy 2.0: CRISPR\/Cas9 genome editing provides novel therapeutic avenues for neuromuscular disorders","volume":"26","author":"Cohn","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib97","first-page":"341","article-title":"CRISPR for neuromuscular disorders: gene editing and beyond","volume":"34","author":"Young","year":"2019","journal-title":"Physiol. (Bethesda)"},{"key":"10.1016\/j.tice.2025.103217_bib98","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"9","key":"10.1016\/j.tice.2025.103217_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99357","article-title":"Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers","volume":"3","author":"Wyatt","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212198","article-title":"CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review","volume":"14","author":"Baba\u010di\u0107","year":"2019","journal-title":"PloS One"},{"issue":"536","key":"10.1016\/j.tice.2025.103217_bib101","doi-asserted-by":"crossref","first-page":"eaay0271","DOI":"10.1126\/scitranslmed.aay0271","article-title":"Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy","volume":"12","author":"Lek","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tice.2025.103217_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.937879","article-title":"Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy","volume":"4","author":"Mariot","year":"2022","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.tice.2025.103217_bib103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtn.2017.02.007","article-title":"CRISPR\/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy","volume":"7","author":"Zhu","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib104","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/sctm.16-0427","article-title":"Selective expansion of skeletal muscle stem cells from bulk muscle cells in soft three-dimensional fibrin gel","volume":"6","author":"Zhu","year":"2017","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/hmg\/ddab218","article-title":"CRISPR gene editing in pluripotent stem cells reveals the function of MBNL proteins during human in vitro myogenesis","volume":"31","author":"M\u00e9rien","year":"2022","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib106","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.stemcr.2021.12.003","article-title":"CRISPR\/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy","volume":"17","author":"Domenig","year":"2022","journal-title":"Stem Cell Rep."},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib107","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.stemcr.2021.08.011","article-title":"CRISPR\/Cas9\/AAV9-mediated in vivo editing identifies MYC regulation of 3D genome in skeletal muscle stem cell","volume":"16","author":"He","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib108","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/cells13110972","article-title":"A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs","volume":"13","author":"Dhoke","year":"2024","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.tice.2025.103217_bib109","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1093\/nar\/gky548","article-title":"Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells","volume":"46","author":"Dastidar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tice.2025.103217_bib110","article-title":"Personalized allele-specific CRISPR-Cas9","author":"Shin","year":"2024","journal-title":"Strateg. myofibrillar Myopathy 6"},{"key":"10.1016\/j.tice.2025.103217_bib111","doi-asserted-by":"crossref","first-page":"104441.362","DOI":"10.1016\/j.nmd.2024.07.371","article-title":"628P Development of a CRISPR\/CasX 4q telomeric region ablation strategy for FSHD1 using an isogenic hiPSC line and a FSHD1 fibroblast cell line","volume":"43","author":"Lama","year":"2024","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib112","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.032201","article-title":"A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9","volume":"11","author":"Sui","year":"2018","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.tice.2025.103217_bib113","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/j.nmd.2016.06.376","article-title":"CRISPR\/Cas9-mediated exon inclusion in Lama2 gene alleviates dystrophic pathology in MDC1A mouse model","volume":"26","author":"Kemaladewi","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib114","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17425247.2022.2100342","article-title":"Progress of delivery methods for CRISPR-Cas9","volume":"19","author":"Yang","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.tice.2025.103217_bib115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14712598.2018.1536119","article-title":"Promise of gene therapy to treat sickle cell disease","volume":"18","author":"Romero","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.tice.2025.103217_bib116","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.tice.2025.103217_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical considerations for delandistrogene moxeparvovec gene therapy in patients with duchenne muscular dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.tice.2025.103217_bib118","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00439-018-1933-9","article-title":"Application of CRISPR\/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases","volume":"137","author":"Cai","year":"2018","journal-title":"Hum. Genet."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12985-024-02286-1","article-title":"Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma","volume":"21","author":"Hadi","year":"2024","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13681","article-title":"Adeno-Associated Virus 8 and 9 Myofibre Type\/Size Tropism Profiling Reveals Therapeutic Effect of Microdystrophin in Canines","volume":"16","author":"Burke","year":"2025","journal-title":"J. Cachex.. Sarcopenia Muscle"},{"key":"10.1016\/j.tice.2025.103217_bib121","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","article-title":"In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy","volume":"19","author":"Kwon","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib122","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib123","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1038\/s41467-023-41769-7","article-title":"Fast, multiplexable and efficient somatic gene deletions in adult mouse skeletal muscle fibers using AAV-CRISPR\/Cas9","volume":"14","author":"Th\u00fcrkauf","year":"2023","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.tice.2025.103217_bib124","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41417-020-0178-7","article-title":"Improvement of muscular atrophy by AAV\u2013SaCas9-mediated myostatin gene editing in aged mice","volume":"27","author":"Weng","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib125","doi-asserted-by":"crossref","first-page":"37051","DOI":"10.1038\/srep37051","article-title":"Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells","volume":"6","author":"Maggio","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.tice.2025.103217_bib126","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1093\/nar\/gkac567","article-title":"Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells","volume":"50","author":"Tasca","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tice.2025.103217_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100895","article-title":"Harnessing nanoparticles for the efficient delivery of the CRISPR\/Cas9 system","volume":"34","author":"Rahimi","year":"2020","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib128","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib129","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1021\/acsami.2c21683","article-title":"Guanidinium-rich lipopeptide-based nanoparticle enables efficient gene editing in skeletal muscles","volume":"15","author":"Zhu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.tice.2025.103217_bib130","doi-asserted-by":"crossref","first-page":"1900061","DOI":"10.1002\/adtp.201900061","article-title":"Polyrotaxane nanocarriers can deliver CRISPR\/Cas9 plasmid to dystrophic muscle cells to successfully edit the DMD gene","volume":"2","author":"Emami","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.tice.2025.103217_bib131","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.actbio.2022.10.015","article-title":"Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles","volume":"154","author":"Li","year":"2022","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib132","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/pharmaceutics13020278","article-title":"Nanomedicine for gene delivery and drug repurposing in the treatment of muscular dystrophies","volume":"13","author":"Andreana","year":"2021","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.tice.2025.103217_bib133","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","article-title":"Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-based genome editing","volume":"14","author":"Wei","year":"2020","journal-title":"Acs Nano"},{"key":"10.1016\/j.tice.2025.103217_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.tice.2025.103217_bib136","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12033-023-00724-z","article-title":"An update on the application of CRISPR technology in clinical practice","volume":"66","author":"Morshedzadeh","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.tice.2025.103217_bib137","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol."},{"issue":"13","key":"10.1016\/j.tice.2025.103217_bib138","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tice.2025.103217_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Mini-review: lethal immunotoxicity in high-dose systemic AAV therapy","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tice.2025.103217_bib140","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2024.2447072","article-title":"Is duchenne gene therapy a suitable treatment despite its immunogenic class effect?","author":"Tang","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tice.2025.103217_bib142","doi-asserted-by":"crossref","unstructured":"Saifaldeen, M., , 2020. CRISPR FokI dead Cas9 system: principles and applications in genome engineering. Cells, 2020. 9(11): p. 2518..","DOI":"10.3390\/cells9112518"},{"issue":"9-10","key":"10.1016\/j.tice.2025.103217_bib143","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/hum.2023.053","article-title":"CRISPR-editing therapy for duchenne muscular dystrophy","volume":"34","author":"Chemello","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.tice.2025.103217_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2025.104424","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"47","author":"Shimizu-Motohashi","year":"2025","journal-title":"Brain Dev."},{"key":"10.1016\/j.tice.2025.103217_bib145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nmd.2024.01.001","article-title":"European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17\u201319, 2023, Barcelona, Spain","volume":"36","author":"Smeets","year":"2024","journal-title":"Neuromuscul. Disord."},{"issue":"9-10","key":"10.1016\/j.tice.2025.103217_bib146","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/hum.2023.059","article-title":"Advances in CRISPR\/Cas9 genome editing for the treatment of muscular dystrophies","volume":"34","author":"Fatehi","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"04","key":"10.1016\/j.tice.2025.103217_bib147","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0044-1791803","article-title":"The Role of CRISPR\/Cas9 in revolutionizing Duchenne's muscular dystrophy treatment: opportunities and obstacles","volume":"11","author":"Ali","year":"2024","journal-title":"Glob. Med. Genet."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib148","doi-asserted-by":"crossref","DOI":"10.1063\/5.0131452","article-title":"Delivery challenges for CRISPR\u2014Cas9 genome editing for Duchenne muscular dystrophy","volume":"4","author":"Padmaswari","year":"2023","journal-title":"Biophys. Rev."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.tice.2025.103217_bib150","article-title":"Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies\u2013Developing Potential Treatments for the Entire Spectrum of Disease","author":"McDonald","year":"2024","journal-title":"Sage Publ. Sage UK Lond. Engl."},{"issue":"7","key":"10.1016\/j.tice.2025.103217_bib151","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tice.2025.103217_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102634","article-title":"Recent applications, future perspectives, and limitations of the CRISPR-Cas system","author":"Park","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.tice.2025.103217_bib153","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/ijms23031832","article-title":"CRISPR therapeutics for Duchenne muscular dystrophy","volume":"23","author":"Erkut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.tice.2025.103217_bib154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jpm8040038","article-title":"Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy","volume":"8","author":"Lim","year":"2018","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tice.2025.103217_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.833833","article-title":"A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review","volume":"10","author":"Chung Liang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"19","key":"10.1016\/j.tice.2025.103217_bib156","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.3390\/cells11192964","article-title":"CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.tice.2025.103217_bib157","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","article-title":"Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy","volume":"3","author":"Moreno","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.tice.2025.103217_bib158","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.tice.2025.103217_bib159","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/ijms20153689","article-title":"CRISPR\/Cas applications in myotonic dystrophy: expanding opportunities","volume":"20","author":"Raaijmakers","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2025.103217_bib160","doi-asserted-by":"crossref","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"19","key":"10.1016\/j.tice.2025.103217_bib161","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.3390\/ijms231912039","article-title":"Nanomedicine for treating muscle dystrophies: opportunities, challenges, and future perspectives","volume":"23","author":"Ahmed","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:15:28Z","timestamp":1785298528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816625004999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":161,"alternative-id":["S0040816625004999"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.103217","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9 gene editing in muscle-related genetic disorders: Restoring function and exercise capacity","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.103217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103217"}}